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Many factors affect the metabolism of tryptophan along the pathway which
leads to the formation of nicotinic acid. The initial step in this pathway involves
cleavage of the pyrrole ring of the indole nucleus (1) to yield formylkynurenine
(2). This enzyme system, which was named tryptophan pyrrolase by Kotake (1),
has also been called the tryptophan peroxidase-oxidase system (2). This enzyme
system is adaptive in that administration of large doses of the substrate (L-
tryptophan) to rats has been shown to increase the activity of the enzyme system
in the liver as much as 10 fold (3, 4). The activity of this enzyme system may
also be increased by substances such as cortisone, histamine, kynurenine and a
variety of other substances (4). Evidence has been presented to show that the
effect of these substances other than tryptophan is mediated via the adrenal-
pituitary system (4). Another factor that appears to affect this reaction, according
to Dalgliesh (5), is thiamin.
Formylkynurenine has been found to be rapidly converted to kynurenine by
formylase (2, 6) or kynurenine formamidase (7). The high activity of this enzyme
system in liver probably accounts for the fact that formylkynurenine could not
be detected in urine (6, 8).
The normal metabolism of kynurenine has been shown to depend upon the
presence of nicotinamide in the form of triphosphopyridine nucleotide (9), and
vitamin B6 in the form of pyridoxal phosphate (10—12). Evidence from several
laboratories indicates that riboflavin may also be Involved in tryptophan metab-
olism (13—16).
Evidence has been presented that pyridoxal phosphate probably functions in
the form of a complex with a metal cation (17). In this regard it should be pointed
out that Jakoby and Bonner (18) found that purified Neurospora kynureninase
was activated by magnesium ions. A highly purified kynureninase obtained by
Wiss and Weber (19) contained vitamin B6 but was not activated by the addition
of other cofactors.
Thus one might expect some alteration of tryptophan metabolism produced by
changes in tissue levels of tryptophan, by alterations in the amounts of the active
forms of niacin, pyridoxine, riboflavin or thiamin in the tissues, by factors af-
fecting the activity of the pituitary-adrenal system, and alterations in tissue
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levels of metal cations which may participate in the action of pyridoxine. The
large number of factors involved make possible several combinations of changes
which might be expected to be reflected in the relative amounts of the various
metabolites of tryptophan excreted in the urine.
Previous studies from these laboratories have shown that antagonists of
pyridoxine like isoniazid and deoxypyridoxine profoundly alter tryptophan
metabolism in patients with tuberculosis (20). The patterns of tryptophan metab-
olites excreted in the urine of patients treated with these drugs were very different
even though the administration of pyridoxine was shown to restore tryptophan
metabolism to normal when either drug was ingested. No conclusive evidence
was obtained to indicate that riboflavin, thiamin or niacin had any influence on
the effects of these drugs on tryptophan metabolism (20).
Many patients with bladder cancer (2 1—23) and certain other types of cancer
(24) have also been found to have abnormal tryptophan metabolism. The pattern
of urinary metabolites was very different in the cancer patients from the patterns
observed in patients treated with isoniazid or deoxypyridoxine. The patterns of
urinary metabolites have been found to be so characteristic that one may readily
determine from examination of the analytical data whether the patient received
isoniazid, deoxypyridoxine, or was a patient with cancer. Studies in progress on
patients with other clinical conditions indicate that there may be other specific
patterns of urinary tryptophan metabolites. However, patients with a variety
of other diseases appear to have completely normal tryptophan metabolism.
Attention was directed toward scleroderma because of the known disturbance
of inorganic metabolism which eventually leads to deposition of calcium and
perhaps other metal ions in the tissues (25). It was anticipated that this abnormal
inorganic metabolism might be reflected in the action of pyridoxine in tryptophan
metabolism. It was found that these subjects did have abnormal tryptophan
metabolism of a type unlike that seen in any other clinical condition thus far
studied. This report concerns the nature of tryptophan metabolism in scleroderma
(acroscierosis), and the effect of pyridoxine, niacinamide and disodium
ethylenediaminetetra-acetic acid on the urinary excretion of products of this
metabolic pathway.
EXPERIMENTAL
Subjects. The subjects used in these studies have been described in a previous publication
(26). They were kept in a special metabolic research ward adjacent to the laboratories.
Analytical Methods. The 24 hour urine collections were made as previously described (27).
Routine determinations of urinary N-methyl-2-pyridone-5-carboxamide, kynurenic acid
xanthurenic acid, aromatic amine fraction A, anthranilic acid glucuronide, o-aminohippuric
acid, anthranilic acid, kynurenine, Naacetylkynurenine, and 3-hydroxykynurenine were
made as previously described (27—29). Paper chromatography was done on all of the aromatic
amine fractions to provide a qualitative check on the quantitative determinations. (9, 28).
Supplements. The disodium salt of ethylenediaminetetraacetic acid (Endrate)' was given
intravenously (26). Before and during treatment 24 hour urine collections were made and
1 "Endrate" was kindly furnished by Rodney P. Gwinn, M.D., Abbott Research Lab-
oratories, North Chicago, Illinois.
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2.0 gin. (9.8 mmoles) of L-tryptophan were administered in the form of four 0.5 gm. tablets2.
The vitamin supplements were standard pharmaceutical preparations.
iStudy Schedule. Case I (P.W., hospital number 309815) and Case II (M.M., hospital
number 311414) were studied on the first admission prior to the start of Na2EDTA treat-
ment. These patients were given 3 weekly courses of 5 days each of intravenous Endrate as
described (26). During the last 4 days of the third course of Endrate the studies were re-
peated. A 24 hour urine sample was collected and 2.0 gm. of L-tryptophan was administered.
At the end of the second 24 hour period the subject was started on 50 mgm. of pyridoxine
hydrochloride twice daily intramuscularly. After 24 hours of pyridoxine treatment a second
2.0 gm. of L-tryptophan was given and the 24 hour urine collection following the administra-
tion of tryptophan was saved. Pyridoxine was given during this last 24 hour collection. Thus
24 hour urine collections were obtained before and after tryptophan without and with
pyridoxine administration and Endrate was given daily during this period.
Case III (G.M., hospital number 312597) was admitted at the same time that Cases land
II returned for further studies. Before therapy was started the biochemical studies were
repeated on the 3 subjects. Two 24 hour urine collections were made and 2.0 gin. of I
tryptophan were administered. Two more 24 hour urine collections were made after the
tryptophan and the subjects were started on 50 mgm. of pyridoxine hydrochloride twice
daily intramuscularly. After another 24 hour urine collection was made the subjects were
again given 2.0 gm. of tryptophan. Two more 24 hour urine collections were made and the
pyridoxine administration was discontinued. The patients were then started on 3 weekly
5-day courses of Endrate intravenously. During the last 2 days of each course of Endrate a
24 hour urine was collected before and after administration of 2.0 gm. of L-tryptophan. At
the end of the third course of Endrate the subjects were all started on 400 mgm. of nicotin-
amide daily, given in four equal doses between 8 a.m. and 8 p.m. After 48 hours on niacin
each subject collected a 24 hour urine before and after a 2.0 gm. dose of tryptophan. Intra-
muscular pyridoxine was then given in addition to the niacin supplement and the patients
collected another 24 hour urine sample before and after a 2.0 gm. tryptophan supplement.
The urine samples were analyzed promptly after they were collected, usually within 2 or
3 days after collection. The eamples were stored at 0—3°C. from the time of collection until
they were analyzed.
Since the colorimetric method used for xanthurenic acid determination (30) in the first
study on Case Land Case II was unsuitable in the presence of the large amount of Endrate in
the urine a new fluorometric determination was developed for xanthurenic acid measure-
ment2. This procedure gave excellent recoveries of added xanthurenic acid and will be
described in detail elsewhere.
RESULTS
The pathway of tryptophan metabolism under consideration is shown in Fig.
1. In these studies the other pathways open to this amino acid have not been
considered.
Since these subjects excreted the metabolites of tryptophan in normal quan-
tities prior to the ingestion of tryptophan the basal or pre-tryptophan values were
not shown. The usual basal values found with these methods may be obtained
from previous publications (28, 31, 32). All of the data have been recorded in
terms of the increased excretion of the metabolites after ingestion of the 2.0 gm.
supplement of the amino acid. The average normal values obtained for the in-
2 The tryptophan was compressed into 0.5 gin. tablets for these studies through the
courtesy of Rodney P. Gwinn, M.D., Abbott Research Laboratories, North Chicago,
Illinois.
Satoh, K., and Price, J. M. Unpublished data.
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FIG. 1. An abbreviated diagram of the metabolic pathway from tryptophan to nicotinic
acid and N-methyl-2-pyridone-5-carboxamide, showing the relationship of the various
metabolites to one another.
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FIG. 2. Themetabolic response of subjects P.W. and M.M. to treatment with Na,EDTA
(EDTA) and Na,EDTA plus pyridoxine (EDTA + B6). The values before any treatment (0)
were abnormally high for both subjects.
creased urinary excretion of these metabolites are shown in Fig. 4. These values
represent the average of 20 subjects with no known disease. The greatest increase
in excretion of these metabolites (in micromoles) by normal subjects after inges-
tion of 2 gm. of L-tryptophan were as follows: kynurenine, 60; acetylkynurenine,
14; o-aminohippuric acid, 58; kynurenic acid, 75; 3-hydroxykynurenine, 45;
xanthurenic acid, 37.
Fig. 2 shows the data obtained during the first admission of P.W. and M.M.
It was evident that both of these subjects had profoundly abnormal tryptophan
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metabolism under the conditions used in these studies, and subject P.W. was
the more abnormal of the two. Both subjects excreted abnormal amounts of
kynurenine, kynurenic acid, acetylkynurenine, and hydroxykynurenine following
tryptophan "loading" prior to treatment. The metabolism of both subjects
changed toward normal after 2 weeks of treatment on Na2EDTA, and subject
M.M. had essentially a normal response to tryptophan. When the pyridoxine
was added to the treatment there was further improvement from a metabolic
standpoint.
Fig. 3 shows that the response to tryptophan supplementation was abnormal
in all 3 subjects prior to treatment. Subjects M.M. and G.M. had a normal
response to tryptophan during the parenteral administration of pyridoxine, but
subject P.W. only partially responded to this treatment. During administration
of Na2EDTA subjects M.M. and G.M. remained normal except that G.M. tended
to become abnormal again on the 15th day of treatment. The administration of
nicotinamide had little effect on the metabolic patterns, but on nicotinamide
plus pyridoxine subjects M.M. and G.M. responded in a normal manner.
Subject P.W. was almost normal after 10 days treatment with Na2EDTA in
the second study (Fig. 3). Otherwise she had an abnormal response to tryptophan
"loading" in every instance.
Since the response to a tryptophan load by these subjects resembled the pattern
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Fia. 3. Levels of urinary metabolites excreted by the 3 subjects during the second study.
Subjects P.W. and M.M. were both abnormal prior to treatment (0) and these results were
similar to those obtained with these subjects on their previous admission (Fig. 2). The
effects of pyridoxine (B6), 5, 10, and 15 days on chelation with Na2EDTA and the administra-
tion of nicotinamide (NA) and nicotinamide plus pyridoxine (NA + B6) are shown. The
xanthurenic acid value for subject P.W. on the 5th day of chelation was lost. Subject P.W.
was the least responsive to therapy, while subject M.M. had completely normal tryptophan
metabolism after chelation.
MM.
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FIG. 4. A comparison of the pre-treatment metabolic response of subject P.W. to
tryptophan loading (Fig. 3), as compared with the average response of 20 subjects with no
known disease and a subject who ingested isoniazid and later deoxypyridoxine. As in Figs.
2 and 3, the values recorded represent the micromoles of increase in the excretion of the
various metabolites after the ingestion of 9.8 millimoles of L-tryptophan (post-tryptophan
values minus the average pre-tryptophan values). The metabolic patterns seen in subject
P.W., in isoniazid treatment, and in deoxypyridoxine treatment were different from one
another and all three conditions were abnormal. The subject receiving isoniazid or deoxy-
pyridoxine had normal metabolism prior to administration of the drugs, or if he was also
given pyridoxine (75 mgm. daily) (20). The "patterns" of metabolites for subjects P.W.,
M.M., and G.M. were similar to each other but the quantities of the various metabolites
excreted by subjects M.M. and G.M. were less than those excreted by subject P.W.
of metabolites seen in pyridoxine deficiency, the metabolic "pattern" shown by
P.W. was compared with that seen in a patient who was ingesting either isoniazid
or deoxypyridoxine (Fig. 4). These values were taken from data collected in a
previous study (20). It is evident that the pattern of metabolites in the sclero-
derma patient was different from that seen in the subject ingesting isoniazid or
deoxypyridoxine. Furthermore, these effects of isoniazid and deoxypyridoxine
on tryptophan metabolism could be completely overcome by the administration
of 75 mg. of pyridoxine hydrochloride daily, while subject P.W. responded only
partially to 100 mg. of this vitamin daily.
It should also be pointed out that the subjects with scieroderma (acrosclerosis)
excreted less hydroxykynurenine than kynurenine. When isoniazid or deoxypyri-
doxine were given to human subjects 3-hydroxykynurenine was the chief uri-
nary metabolite of tryptophan (20). It would appear that in the present studies
some defect in kynurenine hydroxylation was evident (Fig. 3 and 4).
DISCUSSION
There appears to be little doubt that these 3 subjects with scleroderina (acro-
sclerosis) had abnormal tryptophan metabolism. The pattern of the metabolites
in the urine after ingestion of tryptophan resembled, but was not identical with,
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results obtained in studies on the antimetabolites of pyridoxine (20). Normal
metabolism of kynurenine and hydroxykynurenine requires vitamin B6 as a
cofactor for the kynureninase reaction (10) and for kynurenine transaminase
(11, 12). Metzler, Ikawa, and Snell (17) have presented evidence that pyridoxal
phosphate functions with a metal cation to form a chelate which may be the
active form of the coenzyme. The metal ion which functions in these reactions
involving the metabolism of kynurenine and hydroxykynurenine in vivo are
unknown. However, Jakoby and Bonner (18) found that the activation of purified
kynureninase by calcium ions was quite variable, but magnesium ions always
activated their preparations.
One would expect, therefore, that enzymes dependent upon pyridoxal phos-
phate would show decreased activity if there was a deficiency of pyridoxine or
in the presence of a deficiency or an imbalance of metal cations. A defect involving
only pyridoxine would be expected to respond to pyridoxine administration, while
a defect involving a metal ion imbalance or deficiency might respond to large
amounts of pyridoxine or to a correction of the metal ion imbalance. Since these
subjects responded biochemically to either pyridoxine or to Na2EDTA, it is
suggested that the abnormal tryptophan metabolism in scleroderma (acro-
sclerosis) may be due to a metal ion imbalance in the tissues. In view of the fact
that kynureninase has been activated by magnesium ions, one might suspect
that the abnormal tryptophan metabolism observed depends upon a functional
deficiency of magnesium ions. Na2EDTA removed large amounts of zinc in these
(26) and other (33) studies, and probably removed large amounts of calcium
(34). Since patients with scieroderma often eventually develop calcium deposits
ii the soft tissues (25), it is possible that the abnormal metabolism observed in
these patients was the result of a functional deficiency in tissue magnesium. A
patient with a severe metal ion imbalance would not be expected to respond well
to pyridoxine, and such was the case with P.W. This patient was most nearly
normal in her response to tryptophan when she received pyridoxine followed by
Na2EDTA.
When human subjects were given the pyridoxine antagonists, isoniazid or
deoxypyridoxine, severe disturbances in tryptophan metabolism resulted, which
were quantitatively more severe than the results obtained with the most ab-
normal subject with scleroderma (20). These antagonists were completely over-
come by the administration of pyridoxine, probably because there was a normal
balance of tissue metal ions to effectively utilize the pyridoxine supplements.
The metabolism of tryptophan supplements during ingestion of isoniazid or
deoxypyridoxine led to the urinary excretion of quantities of 3-hydroxykynuren-
me far in excess of the quantities of kynurenine (20). In untreated scleroderm.a
(acrosclerosis) the kynurenine excretion always exceeded the excretion of 3-
hydroxykynurenine. In this disease, therefore, there must be some partial inhibi-
tion of kynurenine hydroxylase. Further evidence for this was the fact that
kynurenic acid and o-aminohippuric acid excretion remained high or increased
when the kynurenine excretion decreased following supplementation with vitamin
B6. Since kynurenine hydroxylase requires niacin in the form of triphosphopyri-
dine nucleotide (9), large amounts of niacin were administered to the 3 subjects.
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However, niacin or niacin plus vitamin B6 failed to correct the metabolism of
subject P.W.
The administration of CaNa2EDTA or Na2EDTA to subjects with other condi-
tions often resulted in symptoms suggesting pyridoxine deficiency (33, 34). These
symptoms disappeared when pyridoxine supplements were given. One might
expect, therefore, that overtreatment of patients with scleroderma might result
in abnormal tryptophan metabolism. This may explain the fact that subject
P.W. had a nearly normal pattern of urinary tryptophan metabolites after 10
days of chelation (Fig. 3) but a very abnormal pattern on the 15th day.
Since the patients improved clinically and biochemically by treatment with
Na2EDTA it would appear that tryptophan metabolic studies may be of use in
diagnosis and in following experimental treatment of the subjects. These bio-
chemical studies appear to be a definite indication of a metabolic defect in sciero-
derma. Whether this metabolic defect is of causal significance in scleroderma is
not known. It is more likely a reflection of a disturbance in inorganic metabolism,
possibly involving calcium, magnesium or other metal ions, which is reflected
through pyridoxal phosphate to an abnormal metabolic disposition of
tryptophan.
These studies illustrate, as have previous studies from these laboratories
(20, 21, 24), that the determination of urinary xanthurenic acid as an indication
of abnormal tryptophan metabolism cannot be expected to reveal all cases of
disturbed metabolism of this amino acid. Xanthurenic acid has been detected in
all normal human urine samples tested and must therefore be regarded as a
normal metabolite of tryptophan (35). Xanthurenic acid has often been called
an "abnormal" metabolite of tryptophan because the colorimetric methods for
its determination will not produce clear-cut evidence for its presence in normal
urine (30), while in certain disease states (36), in pregnancy (37) and other
conditions xanthurenic acid has been detected in the urine. Although subjects
with scieroderma did not excrete abnormal amounts of xanthurenic acid either
before or after supplementation with tryptophari, it was readily detected in the
urine by methods previously described (35).
From a metabolic standpoint it would appear that subjects M.M. and G.M.
may be maintained within the normal limits of these studies by the administra-
tion of pyridoxine. Subject P.W., however, responded poorly to pyridoxine. The
significance of these observations remains unknown.
SUMMARY
Three female patients with scieroderma (acroselerosis) were found to have
abnormal tryptophan metabolism, characterized by an abnormally large urinary
excretion of kynurenine, hydroxykynurenine, kynurenic acid, and Naacetyl
kynurenine. The subjects excreted normal amounts of xanthurenic acid, before
and after the ingestion of loading doses of L-tryptophan.
During therapy with disodium ethylenediaminetetraacetic acid (Na2EDTA)
the tryptophan metabolism became nearly normal in one patient and normal in
a second. The simultaneous administration of Na2EDTA and pyridoxine consider-
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ably improved the tryptophan metabolism in the subject who was the less respon-
sive to Na2EDTA alone.
During a second course of NaEDTA both subjects responded in a manner
similar to the first clinical trial. A third patient was found to have normal trypto-
phan metabolism after treatment with NaEDTA or pyridoxine.
The simplest explanation of the biochemical data on tryptophan metabolism
in these three patients would be as follows: In acleroderma (acrosclerosis) there
was an abnormal urinary excretion of kynurenine and its metabolites after oral
administration of tryptophan. The administration of pyridoxine or pyridoxine
plus nicotinamide partially corrected the metabolic abnormality. The efficacy of
pyridoxine plus Na2EDTA could be explained on the basis of a decrease in tissue
calcium, zinc (and possibly other cations) making it possible for the metal ions
normally functioning with pyridoxal phosphate to be utilized more advanta-
geously. The data in the literature suggest that this metal which is unblocked
for normal function may be magnesium.
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